^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
Published date:
01/22/2022
Excerpt:
The purpose of this study was to evaluate the efficacy and safety of PD-1 inhibitor combined with nab-paclitaxel plus gemcitabine (AG) chemotherapy versus AG chemotherapy in the first-line treatment of advanced pancreatic cancer....Among the 20 patients with KRAS and TP53 co-mutation, there were 13 patients treated with AG chemotherapy and 7 patients treated with PD-1 + AG chemotherapy. PFS and OS were compared between the two groups, see Figure 5A and B. The results showed that the addition of immunotherapy did prolong the OS of patients with KRAS and TP53 co-mutation (8.00 months vs 10.20 months, P = 0.004).
Secondary therapy:
gemcitabine + albumin-bound paclitaxel
DOI:
https://doi.org/10.2147/CMAR.S349442
